Calprotectin and SARS-CoV-2: A Brief-Report of the Current Literature
In late December 2019, a novel coronavirus (lately referred to as SARS-CoV-2) spread in the city of Wuhan, China, causing an outbreak of unusual viral pneumonia. In many people, the disease is mild and self-limiting, but in a considerable number of patients, the disease may present more severe or ev...
Main Authors: | Mauro Giuffrè, Luigi Vetrugno, Stefano Di Bella, Rita Moretti, Debora Berretti, Lory Saveria Crocè |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Healthcare |
Subjects: | |
Online Access: | https://www.mdpi.com/2227-9032/9/8/956 |
Similar Items
-
The Usefulness of Tissue Calprotectin in Pediatric Crohn’s Disease—A Pilot Study
by: Edyta Szymanska, et al.
Published: (2023-01-01) -
COVID-19-Induced Thrombosis in Patients without Gastrointestinal Symptoms and Elevated Fecal Calprotectin: Hypothesis Regarding Mechanism of Intestinal Damage Associated with COVID-19
by: Mauro Giuffrè, et al.
Published: (2020-09-01) -
Spontaneous Rectal Perforation in a Patient with SARS–CoV-2 Infection
by: Mauro Giuffrè, et al.
Published: (2020-10-01) -
Impact of Fecal Calprotectin Measurement for Inflammatory Bowel Disease in Children with Alarm Symptoms
by: Burcu Güven, et al.
Published: (2022-06-01) -
Fecal calprotectin levels in preterm infants with and without feeding intolerance
by: Rehab Moussa, et al.
Published: (2016-09-01)